[go: up one dir, main page]

MX2022002941A - Cristal de derivado de 1,3,5-triazina o solvato del mismo y metodo para producir el mismo. - Google Patents

Cristal de derivado de 1,3,5-triazina o solvato del mismo y metodo para producir el mismo.

Info

Publication number
MX2022002941A
MX2022002941A MX2022002941A MX2022002941A MX2022002941A MX 2022002941 A MX2022002941 A MX 2022002941A MX 2022002941 A MX2022002941 A MX 2022002941A MX 2022002941 A MX2022002941 A MX 2022002941A MX 2022002941 A MX2022002941 A MX 2022002941A
Authority
MX
Mexico
Prior art keywords
solvate
same
producing
triazine derivative
crystal
Prior art date
Application number
MX2022002941A
Other languages
English (en)
Inventor
Hiroyuki Kai
Toshikatsu Maki
Shinichi Oda
Kazunori Ban
Koichi Tsubone
Masahiro Hosoya
Yuki Murakami
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of MX2022002941A publication Critical patent/MX2022002941A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/04—Formation of amino groups in compounds containing carboxyl groups
    • C07C227/06—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/04—Formation of amino groups in compounds containing carboxyl groups
    • C07C227/06—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid
    • C07C227/08—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid by reaction of ammonia or amines with acids containing functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/14—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of carbon skeletons containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se relaciona con un cristal de un derivado de 1,3,5-triazina o un solvato del mismo, y con un método para producirlo. La presente invención se relaciona con un cristal de un compuesto representado por la Fórmula (I) o un solvato del mismo, y con una composición farmacéutica que contiene el mismo. La presente invención también se relaciona con un cristal de un compuesto representado por la Fórmula (I), o con un solvato del mismo.
MX2022002941A 2019-09-19 2020-09-18 Cristal de derivado de 1,3,5-triazina o solvato del mismo y metodo para producir el mismo. MX2022002941A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019170340 2019-09-19
JP2020122749 2020-07-17
PCT/JP2020/035378 WO2021054421A1 (ja) 2019-09-19 2020-09-18 １，３，５－トリアジン誘導体またはその溶媒和物の結晶およびその製造方法

Publications (1)

Publication Number Publication Date
MX2022002941A true MX2022002941A (es) 2022-04-06

Family

ID=74884075

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002941A MX2022002941A (es) 2019-09-19 2020-09-18 Cristal de derivado de 1,3,5-triazina o solvato del mismo y metodo para producir el mismo.

Country Status (11)

Country Link
US (1) US12312327B2 (es)
EP (1) EP4032884A4 (es)
JP (1) JP6873534B1 (es)
KR (1) KR20220066307A (es)
CN (2) CN117843615A (es)
AU (1) AU2020348089B2 (es)
BR (1) BR112022004398A2 (es)
CA (1) CA3155142A1 (es)
MX (1) MX2022002941A (es)
TW (1) TWI889708B (es)
WO (1) WO2021054421A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021230308A1 (ja) * 2020-05-15 2021-11-18 塩野義製薬株式会社 不純物の生成を抑制した医薬組成物
CN113773300B (zh) * 2021-09-27 2022-10-11 成都施贝康生物医药科技有限公司 磺酰胺类化合物、其制备方法及用途
WO2024169781A1 (zh) * 2023-02-15 2024-08-22 南京明德新药研发有限公司 嘧啶酮衍生物及其在药学上的应用
WO2025255215A1 (en) 2024-06-05 2025-12-11 Shionogi-Apnimed Sleep Science, Llc Methods and compositions for treating sleep apnea

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2249589T3 (es) 2001-05-18 2006-04-01 Abbott Laboratories Trisustituido-n-((1s)-1,2,3,4-tetrahidro-1-naftalenil)benzamidas que inhiben receptores que contienen antagonistas p2x3 y p2x2/3.
CA2573565A1 (en) 2004-07-22 2006-02-02 Duska Scientific Co. Method of diagnosing, monitoring and treating pulmonary diseases
WO2010092966A1 (ja) 2009-02-13 2010-08-19 塩野義製薬株式会社 新規トリアジン誘導体およびそれを含有する医薬組成物
ES2450891T3 (es) 2009-06-22 2014-03-25 F. Hoffmann-La Roche Ag Bifenilamidas útiles como moduladores de receptores P2X3 y/o P2X2/3
KR101867110B1 (ko) 2010-08-10 2018-06-12 시오노기 앤드 컴파니, 리미티드 트라이아진 유도체 및 그것을 함유하는 진통 작용을 갖는 의약 조성물
CN103476770B (zh) 2010-11-25 2017-02-15 拉蒂欧制药有限责任公司 阿法替尼盐和多晶型物
WO2013089212A1 (ja) 2011-12-15 2013-06-20 塩野義製薬株式会社 置換トリアジン誘導体およびそれらを含有する医薬組成物
AU2013335374B2 (en) * 2012-10-25 2018-04-12 Fisher & Paykel Healthcare Limited Pressure relief arrangement for open surgery insufflation system
TWI637949B (zh) * 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
CA2921395C (en) 2013-08-23 2022-04-26 Afferent Pharmaceuticals Inc. Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough
PT3355889T (pt) 2015-09-29 2023-04-26 Afferent Pharmaceuticals Inc Moduladores de recetores de diaminopirimidina p2x3 e p2x2/3 para utilização no tratamento da tosse
AU2019353424B2 (en) 2018-10-05 2022-12-08 Shionogi & Co., Ltd. Medicine for treating chronic cough
WO2021230308A1 (ja) * 2020-05-15 2021-11-18 塩野義製薬株式会社 不純物の生成を抑制した医薬組成物

Also Published As

Publication number Publication date
US12312327B2 (en) 2025-05-27
CN117843615A (zh) 2024-04-09
WO2021054421A1 (ja) 2021-03-25
CA3155142A1 (en) 2021-03-25
TW202124373A (zh) 2021-07-01
JPWO2021054421A1 (ja) 2021-09-30
CN114728931A (zh) 2022-07-08
US20220396561A1 (en) 2022-12-15
EP4032884A1 (en) 2022-07-27
KR20220066307A (ko) 2022-05-24
JP6873534B1 (ja) 2021-05-19
AU2020348089A1 (en) 2022-03-31
AU2020348089B2 (en) 2025-12-18
TWI889708B (zh) 2025-07-11
EP4032884A4 (en) 2023-09-13
BR112022004398A2 (pt) 2022-05-31

Similar Documents

Publication Publication Date Title
MX2022002941A (es) Cristal de derivado de 1,3,5-triazina o solvato del mismo y metodo para producir el mismo.
MX2023013339A (es) Inhibidor del factor b del complemento, y composicion farmaceutica del mismo, metodo de preparacion del mismo y uso del mismo.
CL2023003041A1 (es) Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica
CL2019003154A1 (es) Proceso de preparación de un compuesto intermediario de fórmula (vi) para la preparación de compuestos de cannabidiol. (divisional solicitud 201800079)
BR112021006229A2 (pt) composto, composição farmacêutica, e, método para tratamento de um câncer
BR112020008664A8 (pt) Composto macrocíclico que atua como inibidor de weel e aplicações do mesmo
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
MX2020000261A (es) Nuevos compuestos.
CL2019000266A1 (es) Composición de cannabis.
MX2020007947A (es) Inhibidores de erbb/btk.
MX2020011868A (es) Inhibidores de los receptores erbb.
MX2019007540A (es) Derivados de pirazol como inhibidores de malt1.
CL2020001752A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa.
CL2020000610A1 (es) Compuestos de bisamida que activan el sarcómero y sus usos.
MX2021011606A (es) Compuestos dirigidos a prmt5.
BR112018075433A2 (pt) derivados de piperidinila, processo para sua preparação e composições farmacêuticas contendo-os
MX391414B (es) Compuesto novedoso de bifenilo o sal del mismo.
MX2021008094A (es) Metodos y composiciones para el tratamiento del cancer.
UY37941A (es) Derivados de bencimidazol y sus usos
MX2025003091A (es) Metodo para producir derivado de heterociclideno acetamida
UY38941A (es) Nuevas sulfiliminas o sulfoximinas que contienen compuestos heterocíclicos fungicidas
CO2024006727A2 (es) Compuestos y composiciones macrocíclicos, y métodos para preparar y utilizar los mismos
CO2022010431A2 (es) Nuevo derivado de pirazol
CL2020000376A1 (es) Compuesto pentacíclico.
MX2020004842A (es) Compuestos heterociclicos antiinfecciosos y sus usos.